다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

CLLS

Cellectis (CLLS)

Cellectis SA

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CLLS

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/29	05:30	GlobeNewswire Inc.	Cellectis Reports Financial Results for First Quarter 2024	NASDAQ:CLLS	Cellectis SA
2024/05/28	19:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2024/05/28	05:30	GlobeNewswire Inc.	Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024	NASDAQ:CLLS	Cellectis SA
2024/05/25	05:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2024/05/06	19:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2024/05/06	15:00	GlobeNewswire Inc.	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca	NASDAQ:CLLS	Cellectis SA
2024/05/03	05:30	GlobeNewswire Inc.	Cellectis Appoints Arthur Stril as Interim Chief Financial Officer	NASDAQ:CLLS	Cellectis SA
2024/04/30	05:46	GlobeNewswire Inc.	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023	NASDAQ:CLLS	Cellectis SA
2024/04/23	05:30	GlobeNewswire Inc.	Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	NASDAQ:CLLS	Cellectis SA
2024/04/11	05:30	GlobeNewswire Inc.	Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs	NASDAQ:CLLS	Cellectis SA
2024/04/09	05:30	GlobeNewswire Inc.	Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting	NASDAQ:CLLS	Cellectis SA
2024/01/17	06:45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2024/01/17	06:30	GlobeNewswire Inc.	Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)	NASDAQ:CLLS	Cellectis SA
2023/12/23	06:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/12/23	06:30	GlobeNewswire Inc.	Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023	NASDAQ:CLLS	Cellectis SA
2023/12/23	06:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/12/06	06:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/11/18	06:56	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/11/18	06:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/11/18	06:30	GlobeNewswire Inc.	Cellectis’ Shareholders Meeting to be Held on December 22, 2023	NASDAQ:CLLS	Cellectis SA
2023/11/15	21:48	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/11/15	16:30	GlobeNewswire Inc.	Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca	NASDAQ:CLLS	Cellectis SA
2023/11/10	06:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/11/07	06:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/11/07	06:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/11/07	06:30	GlobeNewswire Inc.	Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023	NASDAQ:CLLS	Cellectis SA
2023/11/03	05:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/11/03	05:30	GlobeNewswire Inc.	Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting	NASDAQ:CLLS	Cellectis SA
2023/11/02	05:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA
2023/11/02	05:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CLLS	Cellectis SA

검색 관련기사 보기:NASDAQ:CLLS

1 2 3 4 5 6 7 8 9 10 다음 >>

SatixFy Communications

BPCE 1.135% 30mar2032

Bnp Paribas Issuance

OReilly Automotive

ETFS Long SEK Short EUR

Caisse Depots et Consign...

Oncoclinicas Brasil Serv... ON

Blockchain Moon Acquisit...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관